Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Other Accumulated Expenses: 2012-2025

Historic Other Accumulated Expenses for Arrowhead Pharmaceuticals (ARWR) over the last 10 years, with Sep 2025 value amounting to $10.8 million.

  • Arrowhead Pharmaceuticals' Other Accumulated Expenses rose 2402.55% to $10.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.8 million, marking a year-over-year increase of 2402.55%. This contributed to the annual value of $10.8 million for FY2025, which is 2402.55% up from last year.
  • As of Q3 2025, Arrowhead Pharmaceuticals' Other Accumulated Expenses stood at $10.8 million, which was up 46.59% from $7.4 million recorded in Q2 2025.
  • In the past 5 years, Arrowhead Pharmaceuticals' Other Accumulated Expenses ranged from a high of $10.8 million in Q3 2025 and a low of $17,000 during Q1 2021.
  • Over the past 3 years, Arrowhead Pharmaceuticals' median Other Accumulated Expenses value was $448,000 (recorded in 2025), while the average stood at $2.4 million.
  • Examining YoY changes over the last 5 years, Arrowhead Pharmaceuticals' Other Accumulated Expenses showed a top increase of 2,402.55% in 2025 and a maximum decrease of 21.82% in 2025.
  • Quarterly analysis of 4 years shows Arrowhead Pharmaceuticals' Other Accumulated Expenses stood at $17,000 in 2021, then reached $461,000 in 2023, then declined by 4.56% to $440,000 in 2024, then surged by 2,402.55% to $10.8 million in 2025.
  • Its Other Accumulated Expenses was $10.8 million in Q3 2025, compared to $7.4 million in Q2 2025 and $448,000 in Q1 2025.